Contrast injector firm Medrad has introduced new extravasation detector technology for its Stellant CT injection system.
Medrad XDS uses radiofrequency (RF) wave technology and a physical property called permittivity to detect the start of an extravasation under a patient's skin and signal the Stellant to stop injections until a clinician can examine the patient. The product has been cleared by the U.S. Food and Drug Administration.
Six installations currently are operating at four clinical sites. The Warrendale, PA, company plans to begin full-scale XDS production in the fourth quarter.
Medrad demonstrated the product publicly for the first time this week at the 2007 American Healthcare Radiology Administrators (AHRA) annual meeting in Orlando.
By AuntMinnie.com staff writers
July 11, 2007
Related Reading
Medrad lands large Canadian order, July 10, 2007
Medrad grows revenues, workforce, March 20, 2007
Road to RSNA, Medrad, November 1, 2006
Consorta launches group buy promotions, October 31, 2006
Road to RSNA, Medrad, October 26, 2006
Copyright © 2007 AuntMinnie.com
